Karri v. Oclaro Inc.

District Court, N.D. California·Decided October 8, 2020·No. 3:18-cv-03435·Unknown

Opinion

SAISRAVAN BHARADWAJ KARRI, Case No. 18-cv-03435-JD

Plaintiff, ORDER RE MOTION TO DISMISS v. Re: Dkt. No. 29 OCLARO, INC. et al., Defendants.

This is a securities class action against Oclaro, Inc. and its former directors and officers arising out of Oclaro’s acquisition by Lumentum Holdings, Inc.1 Plaintiff SaiSravan Karri brought suit on behalf of former public stockholders of Oclaro under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. §§ 78n(a), 78t(a), and Securities and Exchange Commission Rule 14a-9, 17 C.F.R. § 240.14a-9. Dkt. No. 20 ¶¶ 1, 9. Karri alleges in an amended complaint that Oclaro’s board of directors solicited approval for the transaction through a proxy statement containing materially false or misleading statements regarding the transaction. See id. ¶¶ 3-7. Defendants’ motion to dismiss, Dkt. No. 29, is granted and denied in part. As alleged in the amended complaint, Oclaro was a leading provider of components used in high-speed optical networks. Dkt. No. 20 (Amended Compl.) ¶ 28. Starting in 2016, Oclaro’s strong performance consistently impressed financial analysts and commentators. Id. ¶¶ 30-58. On November 1, 2017, Oclaro announced its quarterly financial results, which, while strong, showed

1 As a result of a merger with a wholly owned subsidiary of Lumentum, Oclaro no longer exists. some weakness in its sales in China and produced a negative market reaction. Id. ¶ 61. Lumentum first expressed interest in acquiring Oclaro a week later, and Oclaro and Lumentum entered into a nondisclosure agreement in December 2017. Id. ¶¶ 63-64. By mid-December 2017, financial analysts had expressed an optimistic assessment of Oclaro’s prospects. Id. ¶ 65. In early February 2018, Oclaro’s CEO publicly touted Oclaro’s strong financial performance, and discounted the impact of the disappointing aspects of the prior quarter’s financial results. Id. ¶¶ 66-73. Specifically, Oclaro’s CEO stated that the company’s guidance in February 2018 remained consistent with its guidance from three months earlier. Id. ¶ 72. Around the same time, Oclaro’s management decided to revise downward its internal financial projections for the second time in as many months, preparing what has been called the “February Projections.” Id. Commentary in the financial community about Oclaro’s prospects remained favorable. Id. ¶ 74. On February 15, 2018, Lumentum submitted a non-binding written offer to acquire Oclaro at $8.35 per share of Oclaro stock, consisting of $6.60 in cash and $1.75 in Lumentum stock. Id. ¶ 75. According to the amended complaint, this represented a discount on both Oclaro’s target price, id. ¶ 76, and on financial analysts’ recent price targets, id. ¶¶ 58, 65. On February 21, 2018, the Oclaro board discussed Lumentum’s offer, and instructed Oclaro’s CEO to present a counteroffer of $9.90 per Oclaro share. Id. ¶ 76. Financial commentary continued to state that Oclaro’s stock was undervalued. Id. ¶ 78. Oclaro’s management ultimately accepted an offer from Lumentum of $5.60 in cash and 0.636 shares of Lumentum stock for each share of Oclaro stock. Id. ¶ 77. Oclaro’s management provided its financial advisor, Jefferies LLC, with the February Projections, which served as the basis for Jefferies’ valuation analyses and fairness opinion evaluating the transaction. Id. Oclaro did not provide these February Projections to Lumentum. Id. On March 11, 2018, Oclaro and Lumentum executed a merger agreement, which they announced the next day. Id. ¶¶ 80-81. After the merger agreement was signed, Oclaro continued to perform well, and in May 2018, Oclaro’s CEO publicly stated that the previous quarter’s consecutive quarter of double-digit operating income growth. Id. ¶ 82. In June 2018, Oclaro’s board of directors solicited approval of Lumentum’s acquisition of Oclaro through a proxy statement. Id. ¶ 83. The proxy included projections from December and January, the February Projections, and Jefferies’ conclusion that the merger consideration offered by Lumentum was fair, based on the valuation figures (specifically, implied equity reference ranges) that Jefferies calculated from the February Projections prepared and provided by Oclaro’s management. Id. ¶¶ 84, 89. The proxy highlighted Lumentum’s promising prospects as a reason for approving the transaction, but omitted the forecasts that had been provided to Jefferies by Lumentum. Id. ¶ 85. The amended complaint alleges that members of Oclaro’s board signed off on a proxy statement that contained false or misleading statements and omissions about Oclaro’s true value, as reflected by Oclaro’s own price targets, id. ¶ 76, Oclaro’s CEO’s public statements on earnings calls, id. ¶¶ 67-73, and financial analysts’ views of Oclaro’s worth, id. ¶¶ 65, 78. Specifically, the amended complaint alleges that the proxy statement included these false or misleading statements: (1) the January and February Projections themselves, (2) representations about the preparation of the January and February Projections, and (3) valuation figures calculated from the February Projections that were used to evaluate the fairness of Lumentum’s offered consideration. Id. ¶¶ 4, 84; see also Dkt. No. 33-1 at 2-3. The amended complaint also alleges that the failure to include the forecasts provided to Jefferies by Lumentum was a materially misleading omission. Dkt. No. 20 ¶¶ 5, 85; see also Dkt. No. 33-1 at 3. Defendants say that the challenged statements fall within the PSLRA’s safe harbor provision, 15 U.S.C. § 78u-5(c), which applies to forward-looking statements that are accompanied by meaningful cautionary language. Dkt. No. 29 at 9-13; Dkt. No. 35 at 3-8. Defendants also contend that Karri has failed to show that challenged statements of opinion are false. Dkt. No. 29 at 13-18; Dkt. No. 35 at 8-12. Finally, defendants argue that the amended complaint fails to plead that the alleged omission of the Lumentum Forecasts rendered the proxy statement misleading, or that such information was material. Dkt. No. 29 at 18-20; Dkt. No. 35 at I. Legal Standards Well-established standards govern this motion to dismiss. To comply with the pleading requirements of Federal Rule of Civil Procedure 8(a)(2) and survive a Rule 12(b)(6) motion to dismiss, a plaintiff must allege “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim has facial plausibility when the pleaded factual content “allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Twombly, 550 U.S. at 556). In evaluating a motion to dismiss, the Court assumes that the plaintiffs’ allegations are true and draws all reasonable inferences in their favor. Usher v. City of Los Angeles, 828 F.2d 556, 561 (9th Cir. 1987). But the Court need not “accept as true allegations that are merely conclusory, unwarranted deductions of fact, or unreasonable inferences.” In re Gilead Sciences Sec. Litig., 536 F.3d 1049, 1055 (9th Cir. 2008) (internal quotation marks omitted) (quoting Sprewell v. Golden State Warriors, 226 F.3d 979, 988 (9th

Free access — add to your briefcase to read the full text and ask questions with AI

Karri v. Oclaro Inc., (N.D. Cal. 2020).

Karri v. Oclaro Inc. (Karri v. Oclaro Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Virginia Bankshares, Inc. v. Sandberg
501 U.S. 1083 (Supreme Court, 1991)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Securities & Exchange Commission v. Todd
642 F.3d 1207 (Ninth Circuit, 2011)
David G. Mroz v. T. Darrell Lee
5 F.3d 1016 (Sixth Circuit, 1993)
Michael Lacey v. Joseph Arpaio
693 F.3d 896 (Ninth Circuit, 2012)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Rubke v. Capitol Bancorp Ltd.
551 F.3d 1156 (Ninth Circuit, 2009)
In Re Verisign, Inc., Derivative Litigation
531 F. Supp. 2d 1173 (N.D. California, 2007)
Gary Varjabedian v. Emulex Corp.
888 F.3d 399 (Ninth Circuit, 2018)
Karim Khoja v. Orexigen Therapeutics, Inc.
899 F.3d 988 (Ninth Circuit, 2018)
Desaigoudar v. Meyercord
223 F.3d 1020 (Ninth Circuit, 2000)
Sprewell v. Golden State Warriors
275 F.3d 1187 (Ninth Circuit, 2001)